Page 8 - Biocon

Pick-up in biosimilar launches driving Biocon's prospects; stock rises 7.8%

As US launch of Insulin addresses a large market, improved visibility for more launches will keep sentiment elevated

Biocon shares up 6% after Co launches insulin glargine in US market

Biocon Biologics India and its partner Mylan NV launched insulin glargine injection under the brand Semglee in the US market.

Biocon-Mylan launch insulin Glargine at lowest price in US market

The commercialisation in the US of the drug, which already has approval in 45 countries, gives a boost to Biocon's ambitious target of $1 billion in sales through its biologics division by FY22

Weekly trading ideas by Religare Broking: Buy Grasim Industries, Biocon

Grasim is witnessing a breakout from the range where it has spent the last two months

Biocon chairperson Kiran Mazumdar-Shaw tests positive for Covid-19

Shaw adds to the list of high-profile people who have been tested positive in Bengaluru in a span of few weeks, including Karnataka chief minister B S Yediyurappa

Stock calls by Sameet Chavan of Angel Broking: Sell Tata Motors, Biocon

One can see a formation of 'Bearish Engulfing' pattern on Tata Motors' daily chart

Tata Capital to pick minority stake in Biocon Biologics for $30 million

Equity infusion part of a larger $200-300 million round the company plans to raise over the next few months as it eyes an IPO

Itolizumab to be a blockbuster opportunity for Biocon: Kiran Mazumdar-Shaw

We felt that this was the drug that would actually have a role to play in dealing with the cytokine storm that is being seen in Covid-19 patients, says Shaw

MARKET WRAP: Sensex trims losses, ends 12 pts down; Nifty closes at 11,194

All that happened in the markets today

Market Ahead, July 24: All you need to know before the opening bell

Today, a total of 71 companies including ITC, Asian Paints, and Ambuja Cements are scheduled to announce their quarterly results

Biocon Q1 pre-tax profit declines 21% to Rs 252.30 crore, revenue up 14%

High R&D spend, low profitability in research services due to Covid-19 pull down net profit

Cheer in Covid times

Here's the backstory of Biocon's Alzumab which has been approved by the CDSCO for the treatment of Covid-19 in India

Sensex ends 269 pts up, Nifty tops 11,200; RIL m-cap crosses Rs 13.5 trn

All that happened in the markets today

Biocon diversifies business model, enters digital therapeutic segment

To launch Insulia for at-home management of diabetes in collaboration with Voluntis

Covid-19 treatment: A lowdown on possible cure and drugs being used

Business Standard takes a look at the common drugs that are being used in India for treating Covid-19 patients

Pharma industry steps up to cure black marketing of Covid-19 drugs

Some firms are now considering starting their own distribution centres in major cities

Plenty of catalysts for Biocon over the next few months, say analysts

Progress in biologics, projects in the pipeline driving prospects

Biocon eyes international markets to supply Itolizumab for Covid-19 therapy

Its partner Equillium is planning to carry out a clinical trial in the US, which could lead to huge spike in demand for the product

Biocon hits new high on DGCI nod to market Itolizumab for Covid treatment

Itolizumab will be manufactured and formulated as an intravenous injection at Biocon's bio-manufacturing facility at Biocon Park, Bengaluru

Biocon's drug Itolizumab gets regulator nod to treat Covid-19 patients

The drug which has got approval to treat moderate to severe Covid complications will be manufactured as an intravenous injection at Biocon's Bengaluru plant